title: Effect on ocular survival of adding early intensive focal treatments to a two-drug chemotherapy regimen in patients with retinoblastoma.
abstract: OBJECTIVE
  To evaluate vincristine and carboplatin with intensive focal treatments in the management of intraocular retinoblastoma.
  
  
  METHODS
  Noncomparative, retrospective interventional case series.
  
  
  METHODS
  
  
  
  METHODS
  Institutional.
  
  
  METHODS
  Sixteen patients (11 bilateral, 5 unilateral) with intraocular retinoblastoma. Interventional procedures: Patients were treated with eight courses of vincristine and carboplatin. Intensive focal treatments were administered after two courses of chemotherapy.
  
  
  METHODS
  Avoidance of external beam radiotherapy (EBRT) and eye survival.
  
  
  RESULTS
  Twenty eyes (74.1%) were classified as Reese-Ellsworth Group V. All eyes responded to chemotherapy. With a median follow-up of 23 months (range 10 to 33 months) and a median of 5.5 focal treatments per eye (range 0 to 19 treatments), ocular survival was 81%. Eight eyes (30%) in five patients received EBRT.
  
  
  CONCLUSIONS
  Vincristine and carboplatin combined with intensive focal treatments is an effective regimen for patients with intraocular retinoblastoma. This treatment regimen has outcomes comparable to those of more toxic regimens and merits further evaluation.
authors.affiliation: Department of Ophthalmology, University of Tennessee Health Science Center, 930 Madison Avenue, Memphis, TN 38163, USA. mwilson5@utmem.edu
authors.forename: Matthew W
authors.initials: MW
authors.lastname: Wilson
authors.forename: Barrett G
authors.initials: BG
authors.lastname: Haik
authors.forename: Tiebin
authors.initials: T
authors.lastname: Liu
authors.forename: Thomas E
authors.initials: TE
authors.lastname: Merchant
authors.forename: Carlos
authors.initials: C
authors.lastname: Rodriguez-Galindo
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001918:Brachytherapy; D016190:Carboplatin / Q000008:administration & dosage; D003131:Combined Modality Therapy; D017679:Cryotherapy; D018572:Disease-Free Survival; D005260:Female; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D007457:Iodine Radioisotopes / Q000627:therapeutic use; D017075:Laser Coagulation; D008297:Male; D019572:Retinal Neoplasms / Q000188:drug therapy / Q000532:radiotherapy / Q000601:surgery / Q000628:therapy*; D012175:Retinoblastoma / Q000188:drug therapy / Q000532:radiotherapy / Q000601:surgery / Q000628:therapy*; D012189:Retrospective Studies; D016896:Treatment Outcome; D014750:Vincristine / Q000008:administration & dosage
chemical_list: D007457:Iodine Radioisotopes; D014750:Vincristine; D016190:Carboplatin